Form 8-K - Current report:
SEC Accession No. 0001171843-25-000190
Filing Date
2025-01-13
Accepted
2025-01-13 07:09:33
Documents
13
Period of Report
2025-01-13
Items
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 FORM 8-K f8k_011325.htm   iXBRL 8-K 22119
  Complete submission text file 0001171843-25-000190.txt   194667

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE bcrx-20250113.xsd EX-101.SCH 3030
3 XBRL LABEL FILE bcrx-20250113_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE bcrx-20250113_pre.xml EX-101.PRE 22369
15 EXTRACTED XBRL INSTANCE DOCUMENT f8k_011325_htm.xml XML 3670
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-23186 | Film No.: 25524780
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)